SCHEMBL458801

SCHEMBL458801

O=C[C@H](O)[C@@H](O)[C@@](O)(F)[C@H](O)CO

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30500659 1.00 AKR1B1 (0.36) AKR1B1
SCHEMBL31757604 1.00 AKR1B1 (0.36) AKR1B1
SCHEMBL22692164 0.80 AKR1B1 (0.40) AKR1B1
SCHEMBL310198 0.80 AKR1B1 (0.40) AKR1B1
SCHEMBL5841129 0.80 PAX8 (0.33) AKR1B1
SCHEMBL27577900 0.78 AKR1B1 (0.39) AKR1B1
SCHEMBL28317227 0.78 AKR1B1 (0.39) AKR1B1
SCHEMBL27751633 0.78 AKR1B1 (0.39) AKR1B1
SCHEMBL9094838 0.77 AKR1B1 (0.37) AKR1B1
SCHEMBL28300145 0.77 AKR1B1 (0.37) AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117222433-A Medicaments conjugated to hexose phosphate and methods of making and using the same 密西西比州立大学 2023-12-12 CN claimed
US-20230372492-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME MISSISSIPPI STATE UNIVERSITY (US) 2023-11-23 US claimed
EP-4221755-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME Mississippi State University (US) 2023-08-09 EP claimed
WO-2022072425-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME PARK JOO YOUN (US) 2022-04-07 WO claimed
US-20090324682-A1 Medical stent provided with inhibitors of atp synthesis INTERSTITIAL THERAPEUTICS (CH) 2009-12-31 US claimed
EP-1789030-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP claimed
EP-1789107-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP claimed
WO-2006024488-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
WO-2006024490-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
WO-2006024491-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
WO-2006024492-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
US-20060025351-A1 Cancer treatment including glycolytic inhibitors LAMPIDIS THEODORE J 2006-02-02 US claimed
US-20050043250-A1 Cancer treatment including glycolytic inhibitors LAMPIDIS THEODORE J (US) 2005-02-24 US claimed
US-12414934-B2 Combination therapies Aardvark Therapeutics, Inc. (US) 2025-09-16 US disclosed
EP-4582080-A1 DISPENSER FOR MUCOSAL ADMINISTRATION COMPRISING 2-DEOXY-GLUCOSE OR ANALOGUES THEREOF G.ST Antivirals GmbH (AT) 2025-07-09 EP disclosed
WO-2024137472-A2 COMBINATION THERAPIES MEI PHARMA, INC. (US) 2024-06-27 WO disclosed
US-6670330-B1 Treating human breast cancer LAMPIDIS THEODORE J (US) 2003-12-30 US disclosed
US-20030181393-A1 Cancer treatment including glycolytic inhibitors LAMPIDIS THEODORE J (US) 2003-09-25 US disclosed
EP-1322304-A1 MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS Lampidis, Theodore J. (US) 2003-07-02 EP disclosed
WO-2001082926-A1 MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS LAMPIDIS THEODORE J (US) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12414934-B2 Combination therapies PCK2, PDK1, PCK1 AKR1B1 924/4885
US-20090324682-A1 Medical stent provided with inhibitors of atp synthesis ATP5ME, ATP5F1A, ATP5MG AKR1B1 2102/4885
US-20060025351-A1 Cancer treatment including glycolytic inhibitors HIF1AN, ALDOA, G6PD AKR1B1 128/4885
US-20050043250-A1 Cancer treatment including glycolytic inhibitors HIF1AN, ALDOA, G6PD AKR1B1 128/4885
US-20230372492-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME GFPT1, PHPT1, SLC2A1 AKR1B1 2710/4885
US-20030181393-A1 Cancer treatment including glycolytic inhibitors HIF1AN, ALDOA, G6PD AKR1B1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.